Zai Lab Reports Q2 2025 Results: Revenue Grows 9% YoY, VYVGART Utilization Sets Record, and Operating Loss Improves 28% YoY.

Zai Lab announced Q2 2025 financial results, with total revenues growing 9% YoY to $110.0 million. The company reaffirmed its full-year 2025 revenue guidance of $560 million to $590 million. VYVGART reached record patient utilization, and updated national guidelines elevated its role in treating both acute and maintenance gMG. ZL-1310 data presented at ASCO 2025 showed a 67% ORR across all doses, with a differentiated safety profile. Zai Lab is on track to achieve profitability in Q4 2025.